{
  "name" : "dacemirror.sci-hub.se_journal-article_bfa99aa7e31f9ad444b48185afe795f6_abouhussein2019.pdf",
  "metadata" : {
    "source" : "CRF",
    "title" : "Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases",
    "authors" : [ "Dalia M.N. Abouhussein", "Dina Bahaa El Din", "Dina Bahaa El Din Mahmoud" ],
    "emails" : [ "dalia_pharma2006@hotmail.com," ],
    "sections" : [ {
      "heading" : null,
      "text" : "Full Terms & Conditions of access and use can be found at https://www.tandfonline.com/action/journalInformation?journalCode=ilpr20\nJournal of Liposome Research\nISSN: 0898-2104 (Print) 1532-2394 (Online) Journal homepage: https://www.tandfonline.com/loi/ilpr20\nDesign of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases\nDalia M.N. Abouhussein, Dina Bahaa El Din Mahmoud & Ebtehal Mohammad F.\nTo cite this article: Dalia M.N. Abouhussein, Dina Bahaa El Din Mahmoud & Ebtehal Mohammad F. (2019): Design of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban for venous thromboembolism management in paediatric patients and emergency cases, Journal of Liposome Research, DOI: 10.1080/08982104.2019.1576732\nTo link to this article: https://doi.org/10.1080/08982104.2019.1576732\nAccepted author version posted online: 05 Feb 2019.\nSubmit your article to this journal\nView Crossmark data\nDesign of a liquid nano-sized drug delivery system with enhanced solubility of rivaroxaban\nfor venous thromboembolism management in paediatric patients and emergency cases\nDalia M.N. Abouhussein 1* , Dina Bahaa El Din Mahmoud 1 , Ebtehal Mohammad F. 2\n1 Pharmaceutics Department, National Organization for Drug Control and Research (NODCAR), Giza, Egypt.\n2 Department of Pharmacology, National Organization for Drug Control and Research (NODCAR), Giza, Egypt.\n* Corresponding Author:\n-Dalia M.N. Abouhussein; email:dalia_pharma2006@hotmail.com,\nAddress: Department of Pharmaceutics, National Organization for Drug Control and Research (NODCAR), 51 Wezaret Elzeraa st, Agouza., Giza, Egypt.\nTel: +201005103838\nAc ce\npt ed\nM an\nus cr\nipt"
    }, {
      "heading" : "Abstract",
      "text" : "The increasing incidence of venous thromboembolism in paediatric population has stimulated the development of liquid anticoagulant formulations. Thus our goal is to formulate a liquid formulation of poorly-water soluble anticoagulant, Rivaroxaban, for paediatric use and to assess the possibility of its intravenous administration in emergencies. Self-nanoemulsifying drug delivery systems (SNEDDS) were developed and characterized. SNEDDS constituents were estimated from the saturated solubility study followed by plotting the corresponding ternary phase diagrams to determine the best self-emulsified systems. Thermodynamic stability, emulsification, dispersibility, robustness to dilution tests, in vitro dissolution, particle size and zeta potential were executed to optimize the formulations. The optimized formulation, that composed of Capryol 90: Tween 20: PEG 300 (5:45:50), increased rivaroxaban solubility (285.7 fold than water), it formed nanoemulsion with a particle size of 16.15 nm, PDI of 0.25 and zeta potential of -21.8. It released 100.83±2.78% of rivaroxaban after 5 minutes. SNEDDS was robust to dilution with oral and parenteral fluids and showed safety to human RBCs. SNEDDS showed enhanced bioavailability after oral and intravenous administration than the oral drug suspension (by 1.25 and 1.26 fold, respectively). Moreover, it exhibited enhanced anticoagulant efficacy in the prevention and treatment of carrageenan-induced thrombosis rat model.\nKeywords: Rivaroxaban –self nanoemulsifying system – paediatrics – venous thromboembolism – anticoagulant"
    }, {
      "heading" : "Abbreviations",
      "text" : "SNEDDS: Self-nanoemulsifying drug delivery system RIVA: Rivaroxaban Capryol 90: CP90 Tween 20: T20 Castor oil: CS FXA: Factor Xa DTI: Direct thrombin inhibitors VTE: venous thromboembolism PDI: polydispersity index Hb: Hemoglobin RBC: red blood cell HCT: count and hematocrit PT: prothrombin time INR: international normalized ratio Cmax: maximum plasma concentration Tmax: the time to reach the maximum plasma concentration AUC: area under the curve Ac ce pt ed\nM an\nus rip\nt\n1.Introduction\nThromboembolic disorders are considered potential life-threatening diseases that lead to serious cardiovascular complications which eventually result in high death rates. Recently, venous thromboembolism (VTE) has been progressively regarded as a severe clinical problem in the paediatric population since it is associated with significant morbidity and mortality in patients, particularly children with serious underlying conditions as cancer and multiple risk factors that were significantly reported in hospitalized children (Kuhle et al., 2004; Raffini et al., 2009). It has been reported that the annual VTE rate has increased by 70% over the past recent years particularly in neonates and adolescents which are at the highest risk (Raffini et al., 2009; Willmann et al., 2014). Accordingly, the first choice therapy for these disorders is the anticoagulants drugs that can be used either as a treatment strategy or as a prophylaxis against thromboembolism in medium or high risk individuals.\nDirect thrombin inhibitors (DTI) are considered promising anticoagulant drugs over other conventional anticoagulants. They have a low risk of inter-individual variability as they directly bind to thrombin resulting in inactive complexes and they do not require the presence of antithrombin whose levels are not anticipated in paediatrics, especially in serious ill neonates. Besides, they are considered to have more predictable pharmacokinetics. Rivaroxaban (RIVA) is a novel DTI with direct factor Xa (FXa) inhibition properties. RIVA is proved to be safer than and as effective as warfarin in the prevention of embolic stroke in patients who suffer from nonvalvular atrial fibrillation (Fluri et al., 2013). RIVA acts by inhibition of free, fibrin-bound FXa and FXa in the prothrombinase complex; consequently, it prevents the formation as well as the growth of blood clot (Perzborn et al., 2011). RIVA has gained approval as a treatment for the deep vein thrombosis, the acute pulmonary embolism and for the prevention of frequent VTE (Willmann et al., 2014). RIVA is practically insoluble in water and it is classified as BCS class II drug (Use, 2008). After the oral administration of RIVA, the peak plasma concentration is achieved within 2 to 4 h (Cuker et al., 2014).\nRIVA is marketed only as oral tablets since its hydrophobicity hinders the preparation of suitable liquid formulations for oral or parenteral applications that can be properly utilized for paediatric or emergency use. Over the recent years, a great consideration has been focused on selfnanoemulsifying drug delivery systems (SNEDDSs) as a tool to boost the solubility and the bioavailability of numerous drugs. SNEDDS is an isotropic mixture of oil, surfactant and cosurfactant in which the drug can be dissolved. Once SNEDDS is delivered to the gastrointestinal tract, a nanoemulsion with small droplet size is spontaneously formed in which the drug is dissolved. The produced nano-sized emulsion droplets afford a great interfacial surface area for the drug solubilization as well as absorption; consequently, a rapid onset of action can be accomplished (Shaji and Jadhav, 2010). SNEDDSs can solve the problem of the slow and incomplete dissolution of poorly-water soluble drugs by enhancing their solubility with subsequent improvement of the absorption process (Heshmati et al., 2013).\nHence, the essential objective of our study is to develop and evaluate a novel RIVA liquid dosage form (SNEDDS) for both oral and parenteral use. This liquid formulation can be taken orally with or without mixing with water or juices immediately prior to use. Such a liquid formulation can be attractive for paediatric patients or those who experience difficulty in\nAc ce\npt ed\nM an\nus cr\nipt\nswallowing with an interesting possibility of dose tailoring. This formulation is also amenable to be diluted with parenteral solutions to yield RIVA parenteral nanoemulsion when the parenteral route is required as in the emergency situations for hospitalized patients.\n2. Materials and methods\n2.1 Materials\nRivaroxaban (RIVA) was kindly obtained as a gift sample from Hikma Company, Cairo, Egypt. Transcutol HP (Highly purified diethylene glycol monoethyl ether, HLB = 4.2), Capryol TM 90 (propylene glycol monocaprylate (type II), HLB = 6) and Maisine TM 35-1 (glyceryl monolinoleate, HLB = 4) were kindly obtained as a gift from Gattefosse, Castor oil, Oleic acid, Cremophore EL (HLB = 12–14), PEG 300, PEG 400, Tween 20 (HLB = 16.7), Tween 80 (HLB =15), Span 80 (HLB = 4.3), ethanol, triacetin, isopropyl myristate, propylene glycol and isopropyl alcohol and carrageenan were purchased from Sigma–Aldrich, Germany. All other chemicals were of analytical grade.\n2.2 Methods\n2.2.1 Saturated solubility study of RIVA in different vehicles\nIn order to determine the components of SNEDDS, RIVA saturated solubility values were determined in different vehicles. Capryol 90 (CP90) , castor oil (CS) , isopropyl myristate, oleic acid, triacetin and maisine were used as lipid phases, tween 20 (T20), tween 80, span 80, and cremophore were tested as surfactants and PEG 300, PEG 400, transcutol, propylene glycol, ethanol and isopropyl alcohol were incorporated into the study as cosurfactants. An excess amount of RIVA was added to 2 mL of each vehicle in 10 mL glass vials then the mixtures were vortexed to solubilize the drug by the means of a vortex mixer. The mixtures were equilibrated at 25ºC for 48 hours in an isothermal shaker and then centrifuged at 7000 rpm for 10 min to aid the precipitation of the undissolved drug. (Abdelbary et al., 2013). Finally, the supernatant was separated and diluted with a mixture of 1:1 methanol: acetonitrile for the quantification of RIVA content using a validated HPLC method with the following chromatographic conditions: Hypersil C18 column (150 X 4 mm, 5 μm), 20 μL as an injection volume and a mixture of phosphate buffer (pH 3.0): acetonitrile (70:30 v/v) as the mobile phase delivered at 1.00 mL/ min flow rate; the detection was done at 249 nm (Abdallah et al., 2015).\n2.2.2 Construction of ternary phase diagrams\nTernary mixtures of oil, surfactant and co-surfactant were prepared by varying the ratio of the components. The components were mixed in glass vials at 40 ºC with stirring at 200 rpm by means of an isothermal shaker till the homogenization of all the components. Then 1 g of each clear mixture was added to a 250 mL of distilled water at 37 ºC under gentle stirring of 25 rpm (Mahmoud et al., 2014) where the dispersions were evaluated by visual observation. A mixture was marked as a good SNEDDS if it was spontaneously emulsified after its dispersion in water yielding a clear transparent nanoemulsion. Pseudo-ternary phase diagrams were plotted using Sigmaplot ® software; each apex of the triangle represents 100% of each component.\nAc c\npt ed\nM an\nus cr\nipt\n2.2.3 Preparation and evaluation of RIVA loaded SNEDDSs\nThe selected SNEDDSs were prepared and RIVA was incorporated into each system by the aid of sonication (using Crest ultrasonic Corp., New York, USA) until complete solubilization of the drug. All mixtures were stored at room temperature for further characterization (Kang et al., 2004).\n2.3 Characterization and Optimization of RIVA loaded SNEDDS\n2.3.1 Thermodynamic stability\nRIVA SNEDDSs were centrifuged, using Beckman model TJ-6 Centrifuge, U.K; for 30 min at 3500 rpm. The systems were tested for any precipitation or phase separation. Formulations that showed no precipitation of RIVA or any phase separation were subjected to heating-cooling cycles (temperatures of 45 º and 4 ºC, respectively). Eventually, the stable systems that passed the previous cycles were exposed to freeze-thaw cycles (-21 ºC and +25 ºC). Every system was stored for 48 h at each temperature (Shafiq et al., 2007); only the thermodynamically stable systems were exposed for further characterization.\n2.3.2 Rheological properties\nThe study of the rheological behavior of RIVA SNEDDS (0.5 g) was performed utilizing Brookfield Digital Rheometer DV III, USA; that was fitted with CP-40 cone and plate spindle at 25 ºC. Viscosity values of the formulations were recorded. Values of the shear stress versus those of the shear rate were plotted in order to investigate the rheological behavior of the formulated SNEDDSs. Formulae with appropriate viscosity were subjected for further testing.\n2.3.3 Assessment of emulsification time, dispersibility and %transmittance\nEmulsification time is used as a critical tool to assess the effectiveness of the emulsification. Assessment of the spontaneous emulsifying properties of the developed RIVA SNEDDSs was done visually (Kassem et al., 2016). The study was performed in USP type II dissolution apparatus (Hanson Research, USA); one gram of each system was dropped into 500 mL of distilled water with agitation by a rotating paddle at a speed of 50 rpm and the temperature was kept at 37 ºC. Emulsification time was recorded as the time taken to obtain a clear homogenous solution. Samples were tested in triplicates (Mahmoud et al., 2014).\nThe efficiency of the self-emulsification process was judged depending on the following grading system (Mahmoud et al., 2014; Shafiq et al., 2007):\n Grade A: Nanoemulsions that are formed rapidly (within 1 min) and attain a clear or bluish appearance.\n Grade B: Rapidly forming translucent nanoemulsions displaying a bluish-white appearance.\n Grade C: Fine milky emulsions that are developed within 2 min.\nAc ep\nte d\nM an\nus cr\nipt\n Grade D: Dull, grayish white emulsions that take more than 2 min to be formed with a slightly oily appearance.\n Grade E: Systems that show reduced or negligible emulsification with large oil globules on their surfaces.\nSystems of Grade A and Grade B were considered as nanoemulsions and they were selected for further investigation; as they are expected to form a nanoemulsion when they are diluted with the physiological solutions.\nPercentage transmittance is used as an indicative measure of the optical transparency of the nanoemulsions, therefore the % transmittance of the formed emulsions was assessed at 650 nm by means of UV spectrophotometer (Shimadzu, UV-160, Japan) using distilled water as a blank (Mahmoud et al., 2014).\n2.3.4 Simulation of the physiological dilution process after oral administration\nRobustness to dilution study was performed to simulate the physiological dilution process after the oral intake of the formulated SNEDDSs. Dilution of RIVA SNEDDSs with distilled water, 0.1N HCl and phosphate buffer pH 6.4 was done and samples were evaluated visually for any phase separation or drug precipitation after 50, 100 and 1000 fold dilution with each medium (Abdallah et al., 2015; Mahmoud et al., 2014).\n2.3.5 In vitro dissolution test\nThe dissolution test was carried out in 900 mL of 0.6% sodium lauryl sulfate in acetate buffer pH 4.5 as dissolution medium (Souri et al., 2016). The study was performed in USP type II dissolution apparatus (Hanson Research, USA) equipped with a rotating paddle with a speed of 75 rpm at a temperature of 37 ºC ±0.2 ºC to investigate the release of RIVA from the developed SNEDDSs and the suspension of the crude drug (samples containing 10 mg RIVA were instilled into the dissolution medium). Five milliliters samples of the dissolution medium were withdrawn at different time intervals (5, 15, 30, 45 and 60 min) and replaced with equal volumes of fresh dissolution medium; after that the withdrawn samples were analyzed for RIVA content through the previously mentioned validated HPLC method.\n2.3.6 Droplet size analysis and polydispersity index\nMeasuring the droplet size is considered one of the main parameters of the stability of the nanoemulsion as it can be used as a predictive measure for the enhancement of both the absorption and the bioavailability of the drugs (Balakumar et al., 2013). The average droplet size along with the polydispersity index (PDI) of the nanoemulsions was measured using the Malvern zetasizer (Nano ZS90, Malvern instrument Ltd., UK). RIVA SNEDDSs were diluted with double distilled water (50 fold) before analysis. Every sample was analyzed three times and the average results ± SD were recorded (Wang et al., 2010).\nAc ce\npt ed\nM an\nus cr\nip\n2.3.7 Zeta potential\nThe polarity of the formed droplet is a very important parameter in evaluating the emulsification efficiency (Parmar et al., 2011). Zeta potential value can elucidate the stability of any colloidal emulsion. Zeta potential values of RIVA SNEDDSs were determined using the zeta potential analyzer (Nano ZS90, Malvern instrument Ltd., UK). Each formulation was diluted with double distilled water (50 fold). The mean value of three measurements ± SD was recorded (Khattab et al., 2017).\n2.4 Further characterization of RIVA SNEDDSs for parenteral administration\n2.4.1 Robustness to dilution with parenteral fluids\nIn order to assure the compatibility of RIVA SNEDDSs with parenteral solutions, the selected formulations were subjected to 50, 100 and 1000 fold dilution with both 0.9% sodium chloride and 5% glucose IV solutions. The mixtures were evaluated visually for any phase separation or precipitation.\n2.4.2 Determination of pH\nThe pH values of the RIVA SNEDDS formulations were measured using pH meter, Jenway 3310, UK; standardized using pH 4.0, 7.0 and 10 standard buffers.\n2.4.3 Sterilization test\nThe formulated RIVA SNEDDSs were sterilized utilizing autoclaving method at 121 °C and 15 psi for 15 min due to the reported thermal stability of RIVA at high temperatures (Abdallah et al., 2015; Use, 2008). The effectiveness of the sterilization was investigated employing nutrient broth medium and incubation at 37 ºC for 1 week. The study design involved 3 groups: the developed SNEDDSs, negative control medium and positive control medium (that was prepared by the incubation with Bacillus subtilis). SNEDDSs were evaluated for the microbial growth compared to the control samples (Tang et al., 2012).\n2.4.4 In vitro assessment of the hemolytic activity of RIVA SNEDDSs\nThe hemolytic activity is used as an in vitro test for the toxicity investigation. Additionally, it is\nused as a simple, indicative and reliable tool for the prediction of the in vivo membrane damage of the formulations. The developed RIVA SNEDDSs were evaluated for their hemolytic activity against heparinized fresh human whole blood. Healthy human blood samples were purchased from Vacsera, Egypt. Pooled blood samples were subdivided into 4 parts (1.6 mL each), of which 2 parts were spiked with the selected RIVA SNEDDS diluted with 0.9 % NaCl (0.4 mL) to obtain a final concentration of RIVA of 4 µg/mL in all blood samples. Immediately the mixtures were gently agitated for 10 s followed by incubation at 37 °C for 2 h. After the 2 hr period, the mixtures were put into ice for 2 min to terminate the hemolytic activity. The separation of the intact RBCs from the supernatant was performed by the centrifugation of the samples at 3000 rpm for 5 min at 5 °C. The negative control sample (in which all RBCs\nAc ce\npt ed\nM an\nus cr\nipt\nremained intact) was obtained by incubating 1.6 mL of blood with 0.4 mL of 0.9% w/v NaCl solution at 37 °C for 2 h. A positive control sample that represents 100% hemolysis of the blood (where none of the RBCs remained intact) was prepared by incubation of 1.6 mL of blood with 14.4 mL double distilled water at 37 °C for 30 min. The controls were treated with the same procedures as the test samples. The supernatant, 0.3 mL was diluted with 0.9% w/v NaCl solution (4.15 mL) in case of the test samples and the negative control while double distilled water was used to dilute the positive control. Finally, the samples were assayed for hemoglobin content using Spectrophotometer (Shimadzu, UV-160, Japan); the absorbance of the supernatants was measured at 540 nm. The % hemolysis was calculated as follows:\n% Hemolysis = \uD835\uDC34\uD835\uDC4F\uD835\uDC60\uD835\uDC5C\uD835\uDC5F\uD835\uDC4F\uD835\uDC4E\uD835\uDC5B\uD835\uDC50\uD835\uDC52 \uD835\uDC47\uD835\uDC52\uD835\uDC60\uD835\uDC61−\uD835\uDC34\uD835\uDC4F\uD835\uDC60\uD835\uDC5C\uD835\uDC5F\uD835\uDC4F\uD835\uDC4E\uD835\uDC5B\uD835\uDC50\uD835\uDC52 \uD835\uDC50\uD835\uDC5C\uD835\uDC5B\uD835\uDC61\uD835\uDC5F\uD835\uDC5C\uD835\uDC59\n\uD835\uDC34\uD835\uDC4F\uD835\uDC60\uD835\uDC5C\uD835\uDC5F\uD835\uDC4F\uD835\uDC4E\uD835\uDC5B\uD835\uDC50\uD835\uDC52 100−\uD835\uDC34\uD835\uDC4F\uD835\uDC60\uD835\uDC5C\uD835\uDC5F\uD835\uDC4F\uD835\uDC4E\uD835\uDC5B\uD835\uDC50\uD835\uDC52 \uD835\uDC50\uD835\uDC5C\uD835\uDC5B\uD835\uDC61\uD835\uDC5F\uD835\uDC5C\uD835\uDC59 ∗ 100\nwhere Absorbance Test is the absorbance of the test sample, Absorbance Control is the absorbance of the negative control sample and Absorbance 100 is the absorbance of the positive control sample where 100% hemolysis of the erythrocytes occurred.\n2.5 Comparative bioavailability studies\nThe pharmacokinetic study of the prepared RIVA SNEDDS was performed using albino rats of 150 ± 30 g each. All the animal procedures were performed according to the EU Directive 2010/63/EU and to the approved protocol for the use of experimental animal set by the ethics regulations of the general division of the pharmacological research department in the National Organization for Drug Control and Research (NODCAR) No: 191/2018. The study was conducted in parallel groups of the investigated animals; each group consisted of six rats. RIVA suspension was prepared at an equivalent concentration of the tested formulation. The selected RIVA SNEDDS was administered orally to a group of rats; another group received RIVA suspension orally (both by gastric intubation method). Additionally, the third group of rats was given the selected SNEDDS through the intravenous route. The rat dose of RIVA was for oral administration and for parenteral administration (0.9 mg/kg). Blood samples (500 μL) were periodically collected from the retro-orbital venous plexus (Wang et al., 2018) using heparinized needle at 0.5, 1, 2, 4, 6, h post drug administration. The heparinized blood samples were instantaneously centrifuged for 15 min at 3000 rpm. The supernatant layer of plasma was separated kept at -20 ºC for further analytical procedures.\n2.5.1 Determination of RIVA in plasma\nThe amount of RIVA in plasma was quantified using a developed validated HPLC method. Separation of RIVA was done using C18 analytical column with the dimension of 150 X 4 mm, 5 μm, olmesartan as an internal standard and the mobile phase consisted of phosphate buffer (pH 3.0): acetonitrile (70:30 v/v). The mobile phase was delivered at a flow rate of 1.5 mL/ min; 50μL of each sample was injected into the HPLC system and the detection was carried out at a wavelength of 249 nm. Thawed plasma samples (200 μL) were placed into a test tube and mixed with 20 μL of the internal standard solution (15 mg/mL) followed by addition of 0.5 mL of acetonitrile. The tubes were vortexed for 2 min at high speed. Finally, the samples were centrifuged for 20 min at 3000 rpm, and then the supernatant was injected into the HPLC system.\nAc ce\npt ed\nM an\nus cr\nipt\nCalibration curves were constructed by plotting the measured peak area ratios of RIVA to olmesartan versus the concentrations of the standard samples.\n2.5.2 RIVA pharmacokinetic parameters\nThe pharmacokinetic parameters of RIVA were evaluated using the non-compartmental model by WinNonlin1 5.3 software. The maximum plasma concentration (Cmax) and the time to reach the maximum plasma concentration (Tmax) were determined by the graphic evaluation of each profile. The linear trapezoidal rule was employed for calculating the area under the curve (AUC0–24). The relative bioavailability was determined using this equation:\nRelative bioavailability = AUC Test ∗ Dose Reference\nAUC Reference ∗ Dose Test ∗ 100"
    }, {
      "heading" : "Statistical analysis",
      "text" : "Data were presented as the mean of three results ± standard deviation (S.D.). The significance of differences between the mean values of the in vivo evaluation was determined by Student t-test and a P-value of less than 0.05 was considered statistically significant.\n2.6 In Vivo efficiency of the selected RIVA SNEDDS in carrageenan induced thrombosis model in rats\nCarrageenan is a straight-chained sulfur-containing macromolecular polysaccharide that is widely used to induce thrombosis in different animals such as mouse and rat. Conferring to the previous studies, κ-carrageenan can lead to local blood vessel inflammation as well as endothelial cell injury through releasing inflammation factors, which may cause the formation of thrombus (Begum et al., 2015). This model is a simple and non-invasive to the used animals and so it was favored over other models for the animal welfare. Hence, an induced tail thrombosis model in rats was used to evaluate the RIVA SNEDDS antithrombotic activity for both the prophylaxis against and the treatment of the induced thrombosis.\nThe rats were randomly divided into eight groups, each group composed of six rats. Groups were treated as follows; normal control group (each rat was injected intraperitoneally with physiological saline), model carrageenan group (where each rat was injected intraperitoneally with 20 mg/kg carrageenan dissolved in physiological saline), and three prophylaxis groups (where each rat was injected intraperitoneally with 20 mg/kg carrageenan dissolved in physiological saline 24 h after the administration of the drug formulations) and three treatment groups (where each rat was injected intraperitoneally with 20 mg/kg carrageenan dissolved in physiological saline 24 h before the administration of the drug formulations). The animals in the three groups in the prophylaxis and treatment models received the optimized RIVA SNEDDS intravenously, the optimized RIVA SNEDDS orally, or the suspension of the crude RIVA orally (0.9 mg/kg). Blood samples from the venous sinus were collected 48 h after the carrageenan injection. Ac ce\np d\nM nu\nsc rip\nt\n2.6.1 Blood sampling\nBlood samples were collected from the retro-orbital venous plexus by means of fine capillary glass tubing. The blood samples were divided into three portions: the first portion was kept in heparinized tube as a whole blood for the determination of the hematological parameters, the second portion was collected into tubes containing 0.5 mL 3.9 % tri-sodium citrate, and the third portion was centrifuged at 3000 rpm for 10 minutes to separate the plasma for the evaluation of anti-FXa activity.\n2.6.2 Biochemical analysis\nMeasurement of prothrombin time (PT) and international normalized ratio (INR)\nBoth PT and INR are considered the measures of how long it takes the blood to clot. These measurements were carried out according to Spectrum Chemicals Company. This test is based on that the addition of a thromboplastin and CaCl2 to the citrated plasma allows the formation of a stable clot. The time taken for the development of a constant clot is determined in seconds; this time signifies the PT from which the INR can then be estimated.\nAnti-FXa activity\nThis test is based on the inhibitory action of RIVA on the coagulation FXa which specifically cleaves para-nitroaniline (p-NA) linked to a chromogenic peptide. Increasing RIVA concentrations dose-dependently inhibit the activity of FXa on the chromogenic peptide and thereby the release of p-NA (Harenberg et al., 2011). The amount of p-NA released (measured at 405 nm) is then a relation of the residual FXa activity where there is a reverse relationship between the concentration of RIVA and the color developed.\nReagents: R1: ATIII (h) Human Anti-thrombin (ATIII) (HYPHEN BioMed, USA). R2: Factor Xa purified bovine Factor Xa (HYPHEN BioMed, USA). R3: Factor Xa specific chromogenic substrate Chromogenic substrate specific for Factor Xa (CS-11(65)) (HYPHEN BioMed, USA).\nMeasurement of hematological parameters\nHemoglobin (Hb) level, red blood cell (RBC) count and hematocrit (HCT%) were estimated using a semiautomatic hematological analyzer (SWELAB IEO Model). The auto counter utilized blood (20 μL) in a ready prepared diluent (16 mL). The machine’s ability to count cells was based on the principle of the electronic impedance. Besides, the platelet count was carried out according to the method of Wertz and Koepke (Wertz and Koepke, 1977) using a haemocytometer.\nStatistical Analysis\nIn vivo study data were expressed as a mean ± standard error of the means (SEM). Comparisons between means were carried out using one-way ANOVA followed by Tukey–Kramer multiple comparisons test. Statistical analysis was performed using Graph Pad Prism software (version 5);\nAc ce\npt ed\nM an\nus cr\nipt\na probability level of less than 0.05 was accepted as statistically significant."
    }, {
      "heading" : "3 Results",
      "text" : "3.1 Saturated solubility study of RIVA in different vehicles\nThe saturated solubility values of RIVA in various vehicles at room temperature are depicted in Table (2). First, the solubility of RIVA in distilled water was found to be 0.007 mg/mL. Among the investigated oils, CP90 exhibited the maximum RIVA solubility (4.5 mg/mL); followed by CS which solubilized RIVA in a concentration of 4 mg/mL. T20, as a surfactant, revealed the highest RIVA solubility (4mg/mL). Among all the tested vehicles, PEG 300 showed the highest solubility value of 8.5 mg/mL. Based on these results, CP90 and CS were selected as the oil phases, T20 as a surfactant and PEG 300 as cosurfactant for SNEDDSs formulations.\n3.2 Construction of ternary phase diagram\nTernary phase diagrams were plotted to recognize the self-nanoemulsifying points and to select the appropriate concentration of oil, surfactant and co-surfactant for the development of the liquid SNEDDS formulations. These phase diagrams play a vital role in investigating the phase behavior of the designed nanoemulsions. In accordance with the RIVA saturated solubility studies done, C90 and CS were chosen as the oily phase while T20 and PEG 300 were selected as the surfactant and cosurfactant, respectively. Formulations were prepared with the composition shown in Table (1); Fig.1 shows the constructed phase diagrams.\nAt a higher concentration of CS (10, 20%), it can be observed that all the mixture compositions gave a turbid solution with oil globules except the ratio in F6 which showed a translucent solution. All the prepared formulations using 5% CS gave a clear solution. For C90, all the formulations containing 10 or 20% oil yielded a translucent solution while all other the formulations gave a clear solution upon contact with the aqueous medium.\n3.3 Preparation of RIVA loaded SNEDDS\nAll the formulations containing 5% oil phase (which yielded clear solutions with the dilution with water) were selected from the ternary phase diagrams and were loaded with RIVA in a concentration of 2mg/mL.\n3.4 Characterization and Optimization of RIVA loaded SNEDDS\n3.4.1 Thermodynamic stability study\nThe results of the thermodynamic stability test are illustrated in Table (3). Among the prepared six formulations, only F7, F16 and F17 were thermodynamic stable as they exhibited no phase separation or precipitation of RIVA during the centrifugation, heating- cooling cycles nor the freeze-thaw cycles. On the other hand, F8, F9 and F18 precipitated RIVA during freeze-thaw cycles; thus they were excluded from further characterization.\nAc ce\npt ed\nM an\nus cr\nipt\n3.4.2 Assessment of the rheological properties\nThe study of the rheological behavior of the developed RIVA SNEDDS revealed that all the formulations exhibited Newtonian flow as depicted in Fig.2. F7 that was composed of 5% CS showed higher viscosity values (175.8 ± 5.2) than those comprising CP90 as the oil phase (118.8 ± 2.11, 150.7 ± 3.7 in case of F16 and F17, respectively); as illustrated in Table (4). Moreover, increasing the amount of T20 in the formulations led to an increase in their viscosity as observed with F16 and F17.\n3.4.2 Assessment of emulsification time, dispersibility and %transmittance\nAs shown in Table (4), the shortest emulsification time was attained in case of CP 90 based formulations F16 (5 ± 1.1 s) followed by F17 (10 ± 1.5 s); they rapidly formed grade A nanoemulsions upon dilution. On the other hand, F7 that was formulated using CS showed a slower emulsification time (36 ± 2.3 s) forming a slightly translucent (grade B) nanoemulsion. All the tested SNEDDSs (F7, F16 and F17) showed a high % transmittance (> 90%). However, the CP 90 based formulations showed greater % transmittance (93.75 ± 1.9 % and 92.4 ± 1.05 % in case of F16 and F17, respectively) than CS based formulations (91.5 ± 1.1 % in case of F7)."
    }, {
      "heading" : "3.4.3 Robustness to dilution and phase separation study",
      "text" : "As explained in Table (5), the inspected formulations that were composed of CP90 (F16 and F17) exhibited no signs of any precipitation, opacity or separation for 24 h which guaranteed the stability of the formed nanoemulsions. On the contrary, F7 which was composed of CS displayed a turbid appearance when diluted to 50 and 100 fold in case of distilled water, 0.1 N HCl, and phosphate buffer (pH 7.4) and a slightly turbid when diluted to 1000 fold using those media; therefore it was excluded from further characterization.\n3.5 In vitro dissolution test\nThe dissolution profiles of RIVA optimized SNEDDSs (F16 and F17) and the suspension of the crude drug in 900 mL of 0.6% sodium lauryl sulfate in acetate buffer (pH 4.6) were illustrated in (Fig. 3). F17 could successfully release 100.83 ± 2.78 % of RIVA after 5 minutes while the % of RIVA release from F16 and RIVA suspension were 77.92 ± 3.11% and 15.4 ± 2.7 %, respectively.\n3.6 Droplet size analysis and polydispersity index\nThe average droplet size of the examined SNEDDSs after 50 folds dilution ranged from 16.15 to 112.96 nm in case of F17 and F16, respectively. The PDI of both formulations was small (0.282 and 0.25 for F16 and F17, respectively).\nAc ep\nte d\nM an\nus cr\nipt\n3.7 Measurement of Zeta potential\nThe results showed that the tested formulations were negatively charged, with values of −9.5 and\n−21.8 mV for F16 and F17, respectively.\n3.8 Further characterization of RIVA SNEDDSs for parenteral administration 3.8.1 Robustness to dilution with parenteral fluids\nBoth F16 and F17 were robust to dilution with both 0.9% saline solution and 5% glucose solution. They showed no precipitation of RIVA or phase separation upon dilution with these parenteral solutions.\n3.8.2 Determination of pH\npH values of F16 and F17 were 6.4 ± 0.1 and 6.22 ± 0.05, respectively.\n3.8.3 In vitro assessment of the hemolytic activity of RIVA SNEDDSs\nThe tested RIVA SNEDDSs exhibited reasonable in vitro % hemolysis (5 ± 0.14% and 6.2 ± 0.37 in case of F17 and F16, respectively) after 2 h incubation with human blood at a concentration of 4 µg/mL.\n3.8.3 Sterilization test\nThe sterilized F16 and F17 didn't show any signs of microbial growth signified the success of the sterilization process by autoclaving.\n3.9 Comparative bioavailability studies\nFig.4 exhibit the mean plasma concentration time curves of RIVA SNEDDS (F17) after oral administration and intravenous administration compared with the crude RIVA suspension at a dose of 0.9 mg/kg. Pharmacokinetic parameters were listed in Table (6). It can be observed that there is a statistically significant 1.7 fold increase in Cmax of RIVA post oral administration of SNEDDS F17 than RIVA suspension. It is also noticeable that RIVA plasma concentrations increased rapidly after SNEDDS oral administration (tmax= 1 h) when compared to concentrations obtained after the oral administration of drug suspension (tmax= 4 h). Moreover, there was a statistically significant improvement in AUC 0-∞ by 1.25 fold than RIVA suspension. The absolute bioavailability of F17 was 98.27%. It could also be observed that there was a statistically significant difference between the intravenous administration of SNEDDS and the oral administration of RIVA suspension regarding the AUC 0-∞ values. The intravenous administration of SNEDDS F17 exhibited enhanced relative bioavailability of 126.88% when compared to the oral administration of RIVA suspension. Ac ce\npt ed\nM an\nus cr\nipt\n3.10 In Vivo efficiency of the selected RIVA SNEDDS in carrageenan induced thrombosis model in rats\nIn carrageenan model group, swelling and distinct change in color were observed after 4 hours of κ-carrageenan injection as well as in treatment groups before administering any treatment. Whereas this effect was slightly observed in the prophylaxis groups particularly in the group that received RIVA suspension orally (Fig.5). In carrageenan model group, the thrombosis was increased from the time it appeared till 48 hours after administration of carrageenan.\n3.10.1 Effects on prothrombin time (PT) and international normalized ratio (INR) Figure (6), illustrated the results of PT and INR of all groups. It can be observed from Fig. 6 A that the intravenous administration of RIVA SNEDDS F17 before thrombus induction (in the prophylaxis model groups) caused statistically significant prolongation in PT than both the carrageenan model group (by 2.33 fold), normal control group (by 1.78 fold) and oral RIVA suspension group (by 1.52 fold). Moreover, the intravenous administration of the developed SNEDDS to rats post thrombus formation (in the treatment model groups) showed statistically significant prolonged PT than the carrageenan group (by 2.5 fold), normal control group (by 1.91 fold) and oral RIVA suspension group (by 1.76 fold). On the other hand, the oral administration of both RIVA SNEDDS and RIVA suspension (in the prophylaxis groups) exhibited statistically significant increase in PT than the carrageenan group (by 1.54 and 1.53 fold, respectively); however there was no statistically significant difference in PT between the two formulations. Contrarily, oral administration of RIVA SNEDDS after induction of thrombosis caused statistically significant prolongation in PT than RIVA suspension by 1.32 fold. Fig.6B depicted that the intravenous administration of our developed SNEDDS as a prophylactic therapy against thrombosis caused statistically significant increase in INR than carrageenan group (by 4.19 fold), normal control group (2.45 fold) and oral RIVA suspension group (by 1.96 fold). Moreover, administration of this SNEDDS intravenously but as a treatment therapy after thrombus formation led to statistically significant increase in INR than carrageenan group (by 4.11 fold), normal control group (2.41 fold) and oral RIVA suspension group (by 2.49 fold). On the other hand, oral administration of RIVA SNEDDS prior to thrombus formation showed comparable effects to that of the oral RIVA suspension on INR; however both formulations significantly increased INR when compared to the carrageenan group. Administration of RIVA SNEDDS orally post thrombus induction showed statistically significant increase in INR by 2.6 fold than the carrageenan group while the oral RIVA suspension couldn't significantly increase INR.\n3.10.2 Effects on anti-FXa activity\nFigure (7), displayed the effects on anti-FXa activity. In prophylaxis model groups, the activity was obviously increased in case of intravenous SNEDDS, oral RIVA SNEDDS, oral RIVA suspension by 2.38, 2.51 and 2.29 fold, respectively when compared to normal control group and by 2.67, 2.8, 2.56 fold, respectively when compared to carrageenan model group. Similarly, in the treatment model groups, anti-FXa activity was obviously increased in case of intravenous SNEDDS, oral RIVA SNEDDS, oral RIVA suspension by 2.52, 2.34 and 2.43 fold, respectively when compared to normal control group and by 2.82, 2.62, 2.72 fold, respectively when compared to carrageenan model group. However, there were no statistically significant\nAc ce\npt ed\nM a\nus rip\nt\ndifferences between the formulations or the routes of administration in both the prophylaxis and the treatment models.\n3.10.3 Effects on hematological parameters\nFigure (8), presented the effect of the new RIVA SNEDDS on the hematological parameters. As shown in Fig. 8A, Hb level was significantly decreased significantly by 0.26 fold in carrageenan group than the normal control group. This level was increased obviously by 1.37 fold, 1.43 fold, 1.28 fold and 1.41 fold in prophylactic intravenous RIVA SNEDDS, prophylactic oral RIVA suspension, intravenous treatment RIVA SNEDDS, and oral treatment RIVA suspension groups, respectively, as compared to the carrageenan group. There were insignificant differences between all groups regarding RBCs count and Hematocrit % as illustrated in Fig. 8B and C.\nOn the other hand, platelet count was markedly increased by 2.06 fold in the carrageenan model group as compared to the normal control group as depicted in Fig. 8D; this effect was successfully reversed by administration of RIVA. The intravenous administration of RIVA SNEDDS in the prophylaxis group significantly diminished the platelet count by 1.7 and 1.85 fold than the normal control and carrageenan groups, respectively. Additionally, the intravenous administration of this SNEDDS in the treatment model groups caused statistically significant decline in platelet count by 1.64, 1.82 and 1.25 fold than the normal control and carrageenan and oral RIVA suspension groups, respectively. Results also revealed that the oral administration of RIVA SNEDDS and RIVA suspension in the prophylaxis model significantly decreased the platelet count when compared to the normal control group by 1.75 and 1.78 fold, respectively. Moreover, oral RIVA SNEDDS and RIVA suspension significantly decreased the platelet count when compared to the carrageenan group, by 1.88 and 1.89 fold, respectively.\nOn the other hand, in the treatment model groups, the significant decrease in the platelet count was only observed in case of comparing both oral RIVA SNEDDS and RIVA suspension to the carrageenan group."
    }, {
      "heading" : "4. Discussion",
      "text" : "The poor aqueous solubility of some drugs is considered a major drawback in formulating suitable liquid formulations for oral or intravenous administration. SNEDDSs present a perfect approach for enhancing the solubility of the drugs and thus they serve as ideal carriers for the delivery of BCS Class II and IV drugs (Singh et al., 2009). RIVA is an anticoagulant drug that has a very limited solubility in water (0.007 mg/mL) which limits the availability of suitable intravenous formulations. RIVA is a BCS class II drug (Stampfuss et al., 2013; Use, 2008). This study was performed to investigate the role of self-nanoemulsifying formulations to boost the solubility of the anticoagulant drug, RIVA which can be a potential alternative to the conventional marketed tablets. Solubility of the investigated drug in each excipient plays a vital role in determining the stability of the designed formulation to avoid any precipitation or phase separation upon experiencing in situ solubilization (Parmar et al., 2011). Thus, the solubility of RIVA in each of SNEDDS excipients was investigated. Besides, the investigated dose was 2mg/mL which is soluble in each SNEDDS component to ensure the success of RIVA SNEDDS which is in agreement to Kassim et.al (Kassem et al., 2016). Ac ce\npt ed\nM an\nus cr\nipt\nEmulsification is a vital process in the formation of SNEDDS and it is controlled by the good choice of the surfactant and cosurfactant. Surfactant/cosurfactant systems play an important role in this dosage form by getting adsorbed at the globule interface, reducing the surface tension, and thus providing a mechanical barrier to inhibit the incidence of coalescence of the formed globules. Subsequently, a lower amount of free energy will be needed to obtain the emulsion which in turn will enhance its thermodynamic stability (Beg et al., 2012). HLB value of the selected surfactant affects the spontaneity of the process of the emulsification and the globule droplet size. Surfactants that have HLB more than10 favor the formation of o/w nanoemulsions (Kommuru et al., 2001). In addition, the non-ionic surfactants are recommended in the pharmaceutical formulations over other ionic surfactants. Tweens are group of non-ionic surfactants that possess favorable characteristics as they are less toxic, minimally affected by ionic strength or pH change. Moreover, they impart critical micelle concentrations less than other ionic emulsifiers (Kommuru et al., 2001). In our study, the greatest solubility was attained by T20 (HLB 16.7) followed by T80 (HLB 15) then Cremophore EL (HLB = 12–14). Higher HLB surfactants lead to the formation of more stable nanoemulsion upon exposure to water (Kommuru et al., 2001). Besides, polyethylene glycols are stated to be suitable for parenteral formulations due to their safety and low costs (Nayak and Panigrahi, 2012). PEG 300 showed the highest RIVA solubility, thus, both T20 and PEG 300 were selected as a surfactant/ cosurfactant system with CP90 or CS as oil phase for further characterization and optimization.\nNanoemulsions are drug delivery systems that are anticipated to be characterized by their thermodynamic stability during their storage with no precipitation or crystallization. Nevertheless, prolonged storage of SNEDDs may cause the solubilized drug to sediment. This sedimentation may act as seed crystals that can grow larger by time causing phase separation (Parmar et al., 2011). Therefore, it was crucial to investigate the thermodynamic stability of RIVA SNEDDSs. The precipitation of RIVA that was observed in case of F9 and F18 can be attributed to the lower saturated solubility of RIVA in T20 than in PEG 300; as both formulations contained higher % of T20 and lower % of PEG 300 in their composition. Also the precipitation of RIVA in F8 and the stability of F17 can be justified by the lower solubilizing capacity of CS than CP90 for RIVA.\nThe viscosity of SNEDDs is an important parameter particularly when they are intended to be administered parenterally, since systems with high viscosity may encounter problems in the syringeability and eventually imparts difficulties in discharging the formulations from their containers (Ram I. Mahato 2011). The higher viscosity that was obtained in F7 than F16 and F17 could be attributed to the higher viscosity of CS than that of CP90. Additionally, increasing % T20 in the composition of SNEDDSs produced formulations with higher viscosity due to the high viscosity of T20 than PEG 300.\nWhen SNEDDSs are administered orally or parenterally, they become dispersed in the physiological fluids to form a fine a nanoemulsion. Thus, it is important to ensure that the formed nanoemulsion does not experience any precipitation nor phase separation with infinite dilution in the GI fluids (Elnaggar et al., 2009). The shortest emulsification time was produced with F16 (5 ± 1.1 s) that can be justified by having the lowest viscosity value in comparison to the other formulations. CS based formulation (F7) was not amenable to form a clear nanoemulsions upon dilution with different media compared with CP 90 based formulations (F16\nAc ce\npt e\nM an\nu cr\nipt\nand F17). In addition, it formed grade B emulsion after its dispersion in water. This can be justified by the lower solubility values of RIVA in CS than in CP90. Accordingly, F7 was excluded from the evaluation study and CP90 based formulations (F16 and F17) were selected for further evaluation.\nThe increased RIVA % release from the developed SNEDDSs is attributed due to the spontaneous formation of nanoemulsion with reduced globule size that requires low surface free energy at the oil/water interface, which can cause instantaneous solubilization of the drug in dissolution medium (Beg et al., 2012). Moreover, the smaller the globules size of the formed nanoemulsion, the larger the interfacial area that is available for drug dissolution and absorption (Balakumar et al., 2013; Parmar et al., 2011). Consequently, F17 showed higher dissolution rate (100.83 ± 2.78 % of RIVA was released after 5 minutes) in comparison to 77.92 ± 3.11% and 15.4 ± 2.7 % in case of F16 and RIVA suspension, respectively. This may be attributed to the particle size as F17 showed lower particle size (16.15nm) than that of F16 (112.96 nm). Since, self-microemulsifying drug delivery systems (SMEDDSs) are the systems that form microemulsions of droplet size ranged from 100 to 250 nm, while SNEDDSs refer to the formulations that form nanoemulsions of droplet size less than 100 nm (Pouton and Porter, 2008). Accordingly, F16 can be considered as SMEDDS while F17 can be considered as SNEDDS. The droplet size decreased as the percentage of the surfactant in the formula increased which may lead to a greater stabilization of the formed droplets (Lawrence and Rees, 2012; Parmar et al., 2011) . It was reported that the surfactant can cause the interfacial film to condense and hence to stabilize yielding smaller droplet size, while increasing the amount of the cosurfactant may cause inflation of the film (Fahmy et al., 2015; Hosny and Banjar, 2013). These observations are consistent with earlier reports in literature (Agrawal et al., 2015; Shakeel et al., 2014). The smaller PDI values of F16 and F17 (less than 0.5) designated uniform droplet size distribution (Balakumar et al., 2013; Shakeel et al., 2014). In relatively small particle size molecules, dispersions confer a high zeta potential that allows the particles to resist aggregation due to the repulsion of the similarly charged particles (Parmar et al., 2011).\nThe higher zeta potential value of F17 than F16 can be explained by the smaller droplet size of the former as in the relatively small droplet size molecules, dispersions confer a high zeta potential that imparts the particles the ability to resist aggregation as a result of the repulsion forces between the similarly charged particles (Parmar et al., 2011). The negative charge that obtained with zeta potential values of F16 and F17 can be attributed to the use of T20 which is a non-ionic surfactant. Choi et al. reported that most non-ionic surfactants produce a negatively charged potential at neutral pH due to the differential adsorption of the produced ions (H3O+ and OH‾) (Kassem et al., 2016).\nF16 and F17 showed great compatibility with parenteral solutions which signified its suitability to be diluted with these solutions for the intravenous administration. The pH values of both formulations complied with the requirements for the parenteral application as it was reported that a pH limit of 2 to 12 is acceptable for intravenous and intramuscular applications (Söderlind et al., 2003). RIVA sterilized SNEDDSs (F16 and F17) showed acceptable % hemolysis which indicated their safety to human blood components.\nAc ce\npt e\nM a\nus cr\nipt\nThe augmented RIVA plasma concentrations after the oral administration of SNEDDS (1.7 fold\nincrease) can be justified by the formation of a clear nanoemulsion of small droplet size that provided a large surface area for drug dissolution which in turns improved its bioavailability.\nThe insignificant difference in the AUC 0-∞ values between intravenous and oral administration of RIVA SNEDDS signified the ability of the intravenous administration of our developed SNEDDS as an alternative approach in emergency cases when oral route is prohibited.\nHerein for the first time, the anticoagulant effect of RIVA was studied for both its prophylactic and a treatment action for a new liquid formulation administered through both the oral and intravenous routes. RIVA is not administered intravenously due to its poor aqueous solubility; the intravenous administration of RIVA has been investigated in this study using our developed SNEDDS F17. The obtained results proved the enhanced efficiency of RIVA when administered through the intravenous routes for both prophylactic and therapeutic purposes. It could greatly prolong PT and INR thus inhibits thrombus formation than the oral RIVA suspension; this can be attributed to the rapid availability of higher plasma concentrations of RIVA after the intravenous administration. This can be beneficial in emergency cases where fast inhibition of clot formation can be lifesaving. Moreover, our liquid RIVA SNEDDS when administered orally it had comparable effects to the oral suspension which proves that this liquid formulation can alternatively be used for paediatric patients with optimum efficacy. Moreover, oral RIVA SNEDDS showed better results than RIVA suspension regarding PT and INR and this can be justified by the higher bioavailability of the formulated SNEDDS than the suspension (1.25 fold). Generally, this study proved that RIVA had a promising antiplatelet activity beside its anticoagulation effect with particular highlighting on the intravenous administration of our developed SNEDDS as it showed statistically significant decrease in platelet count as compared to the oral RIVA suspension. The results were in accordance with the reported inhibitory effect of RIVA on FXa activity; as it was reported that RIVA inhibits FXa by delaying the thrombin formation as well as the direct inhibition of FXa as it may have a direct effect on the vascular endothelial growth factor secretion and so suppress the coagulation process (Liu et al., 2018)."
    }, {
      "heading" : "5. Conclusion",
      "text" : "In the present investigation, a new liquid RIVA SNEDDS was successfully prepared and optimized. The selected dosage form was composed of CP90 (as oil phase), T20 (as surfactant) and PEG 300 (as cosurfactant) in the ratio of 5:45:50. It succeeded to solubilize the RIVA 285.7 times higher than its solubility in distilled water. The new formula proved to be stable and of appropriate characteristics for both oral and parenteral routes of administration. It was concluded that the designed formula could be used safely and efficiently for the treatment of VTE in patients who suffer difficulty in swallowing as paediatrics or in critical cases that needs a fast intervention treatment."
    }, {
      "heading" : "Acknowledgment",
      "text" : "Authors would like to acknowledge National Organization for Drug Control and Research (NODCAR) for providing all the necessary facilities during the experimental work. Together\nAc ep\nte d\nM an\nus cr\nipt\nwith, the authors are thankful to Hikma and Gattefosse companies for providing some materials as gifts."
    }, {
      "heading" : "Declaration of interest",
      "text" : "The authors report no conflict of interest."
    }, {
      "heading" : "Fig.2: Rheograms of the developed RIVA SNEDDSs.",
      "text" : "Fig.3: In vitro release profiles of RIVA SNEDDSs compared with RIVA suspension.\nFig.4: Plasma concentration–time curve of RIVA SNEDDS after oral and intravenous administration to\nalbino rats.\nFig.5: RIVA anti-thrombic effect on Carrageenan induced thrombus rat model on A) control group B)\nthrombus induced group C) oral prophylactic group D) IV prophylactic group E) standard prophylactic\ngroup F) oral treatment group G) IV treatment group H) standard treatment group.\nFig.6: Effects of rivaroxaban pro.(IV), rivaroxaban pro.(oral), rivaroxaban pro.(standard), rivaroxaban\ntreat.(IV), rivaroxaban treat.(oral) and rivaroxaban treat.(standard) on prothrombin time (PT) and\ninternational normalized ratio (INR) in carrageenan (20mg/Kg) induced-coagulation in rats. Data\nrepresents mean (n = 6-8) ±SEM, (*), (#), ($), and (!) indicate that there is significant difference\n(P<0.05) relative to Control, Carrageenan, rivaroxaban pro.(standard) & rivaroxaban treat.(standard)\ngroups, respectively. Statistical analysis was carried out by one way ANOVA followed by Tukey-"
    }, {
      "heading" : "Kramer Multiple Comparison Test.",
      "text" : "Fig.7: Effects of rivaroxaban pro.(IV), rivaroxaban pro.(oral), rivaroxaban pro.(standard), rivaroxaban\ntreat.(IV), rivaroxaban treat.(oral) and rivaroxaban treat.(standard) on factor Xa activity in\ncarrageenan (20mg/Kg) induced-coagulation in rats. Data represents mean (n = 6-8) ±SEM, (*) and (#)\nindicate that there is a statistically significant difference (P<0.05) relative to Control and Carrageenan\ngroups, respectively. Statistical analysis was carried out by one way ANOVA followed by Tukey-"
    }, {
      "heading" : "Kramer Multiple Comparison Test.",
      "text" : "Figure 8: Effects of rivaroxaban pro.(IV), rivaroxaban pro.(oral), rivaroxaban pro.(standard), rivaroxaban treat.(IV), rivaroxaban treat.(oral) and rivaroxaban treat.(standard) on haematological parameters in carrageenan (20mg/Kg) induced-coagulation in rats. Data represents mean (n = 6-8)\n±SEM, (*), (#), ($), and (!) indicate that there is significant difference (P<0.05) relative to Control,\nCarrageenan & rivaroxaban treat.(standard) groups, respectively. Statistical analysis was carried out\nby one way ANOVA followed by Tukey- Kramer Multiple Comparison Test.\nAc c\npt ed\nM nu\nsc rip\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nAc ce\npt ed\nM an\nus cr\nipt\nTable (1): Composition of ternary mixtures\nFormula\ncode\nType of\noil % Oil\n% Surfactant\n(Tween 20)\n% Co-surfactant\n(PEG 300)\nF1\nCastor\noil\n20 20 60\nF2 20 30 50 F3 20 70 10 F4 10 30 60\nF5 10 40 50 F6 10 80 10 F7 5 35 60 F8 5 45 50\nF9 5 85 10\nF10\nCapryol\n90\n20 20 60\nF11 20 30 50 F12 20 70 10 F13 10 30 60 F14 10 40 50 F15 10 80 10 F16 5 35 60\nF17 5 45 50 F18 5 85 10\nTable (2): Saturated solubility of RIVA in different vehicles.\nSolvent Type Solvent Solubility (mg/mL) ± SD Aqueous media Distilled water 0.007\nOil\nCapryol90 4.5\nCastor oil 3.8\nMaisine 2.47\nIsopropyl myristate 1.466\nTriacetin 0.85\nOleic acid 0.051\nSurfactant\nTween 20 4 Tween 80 3\nSpan 80 2.3\nCremophore 0.96\nCo-surfactant\nPEG 300 8.5\nTranscutol 5\nIsopropyl Alcohol 2.42\nPEG 400 1.94\nPropylene Glycol 0.95\nEthanol 0.19\nAc ce\npt ed\nM an\nus cr\nipt\nTable (3): Thermodynamic stability results of RIVA SNEDDS\nFormula code\nComposition Observed drug precipitation Thermodynamic stability\nF 7\nCastor oil : 5 %\nNo precipitation occurred Stable Tween 20: 35 % PEG 300: 60 %\nRIVA: 2 mg/ml\nF8\nCastor oil : 5 %\nPrecipitation at freeze-thaw cycles Unstable Tween 20: 45 % PEG 300: 50 %\nRIVA: 2 mg/ml\nF9\nCastor oil : 5 %\nPrecipitation at freeze-thaw cycles Unstable Tween 20: 85 % PEG 300: 10 %\nRIVA: 2 mg/ml\nF16\nCapryol 90 : 5 %\nNo precipitation occurred Stable Tween 20: 35 % PEG 300: 60 %\nRIVA: 2 mg/ml\nF17\nCapryol 90 : 5 %\nNo precipitation occurred Stable Tween 20: 45 % PEG 300: 50 %\nRIVA: 2 mg/ml\nF18\nCapryol 90 : 5 %\nPrecipitation at freeze-thaw cycles Unstable Tween 20: 85 % PEG 300: 10 %\nRIVA: 2 mg/ml"
    }, {
      "heading" : "Table (4): Characterization of RIVA SNEDDSs",
      "text" : "Formula Viscosity ± SD (cP)\n% Transmittance ± SD\nEmulsification time ± SD (s)\nGrade of the formed emulsion\nF7 175.8 ± 5.2 91.5 ± 1.1 36 ± 2.3 B\nF16 118.8± 2.11 93.75 ± 1.9 5 ± 1.1 A\nF17 150.7± 3.7 92.4 ± 1.05 10 ± 1.5 A\nAc ce\npt ed\nM an\nus cr\nipt\nTable (5): Results of the dilution of RIVA SNEDDSs with different media\nFormula\nWater 0.1 N HCl Buffer pH 7.4\n50\nfold\n100 fold\n1000 fold\n50\nfold\n100 fold\n1000 fold 50 fold\n100 fold\n1000 fold\nF7 Turbid Turbid Slightly\nturbid Turbid Turbid\nSlightly\nturbid Turbid Turbid\nSlightly\nturbid\nF16 Clear Clear Clear Clear Clear Clear Clear Clear Clear\nF17 Clear Clear Clear Clear Clear Clear Clear Clear Clear\nTable (6): Comparative pharmacokinetic parameters of RIVA in blood following the administration of oral RIVA suspension, oral RIVA SNEDDS and IV RIVA SNEDDS\nParameter Oral RIVA\nSuspension\nOral RIVA\nSNEDDS\n(F17 )\nIV RIVA SNEDDS\n(F17 )\nCmax (ng/mL) 49.33± 1.14 83.76±4.52* -\nTmax (hr) 4±0.404 1±0.202* -\nK (min -1 ) 0.032±0.006 0.029±0.011 0.025±0.007\nAUC 0-t (ng h/mL) 385.7±10.06 403.06±6.36* 394.98±13.04\nAUC 0-∞ (ng h/mL) 1027.76±18.69 1281.509±7.62* 1304.05±19.31*\n- Values are presented as mean ± SD (n=6). - (*) indicates statistical significant difference between the treatments and oral RIVA suspension (p< 0.05)\nAc ce\npt ed\nM an\nus cr\nipt"
    } ],
    "references" : [ {
      "title" : "Investigation of the profile and kinetics of degradation of rivaroxaban using HPLC, TLC-densitometry and LC/MS/MS: Application to preformulation studies",
      "author" : [ "M.A. Abdallah", "M.A. Al-Ghobashy", "H.M. Lotfy" ],
      "venue" : "Bulletin of Faculty of Pharmacy, Cairo University",
      "citeRegEx" : "Abdallah et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Abdallah et al\\.",
      "year" : 2015
    }, {
      "title" : "Formulation of solid self-nanoemulsifying drug delivery systems using N-methyl pyrrolidone as cosolvent. Drug development and industrial pharmacy",
      "author" : [ "A.G. Agrawal", "A. Kumar", "P.S. Gide" ],
      "venue" : null,
      "citeRegEx" : "Agrawal et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Agrawal et al\\.",
      "year" : 2015
    }, {
      "title" : "Development, optimization, and characterization of solid self-nanoemulsifying drug delivery systems of valsartan using porous carriers",
      "author" : [ "S. Beg", "S. Swain", "H.P. Singh", "N. Patra Ch", "M.E. Rao" ],
      "venue" : "pharmacokinetic evaluation. Colloids and surfaces. B,",
      "citeRegEx" : "Beg et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Beg et al\\.",
      "year" : 2012
    }, {
      "title" : "inflammatory biomarkers in carrageenan-induced inflammation",
      "author" : [ "A. Cuker", "D.M. Siegal", "M.A. Crowther", "D.A. Garcia" ],
      "venue" : "Pharmaceutical biology",
      "citeRegEx" : "Cuker et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Cuker et al\\.",
      "year" : 2014
    }, {
      "title" : "tamoxifen citrate: design and optimization. International journal of pharmaceutics",
      "author" : [ "U.A. Fahmy", "O.A. Ahmed", "K.M. Hosny" ],
      "venue" : "AAPS PharmSciTech 16,",
      "citeRegEx" : "Fahmy et al\\.,? \\Q2015\\E",
      "shortCiteRegEx" : "Fahmy et al\\.",
      "year" : 2015
    }, {
      "title" : "rivaroxaban. Cerebrovascular diseases",
      "author" : [ "J. Harenberg", "R. Kramer", "C. Giese", "S. Marx", "C. Weiss", "M. Wehling" ],
      "venue" : null,
      "citeRegEx" : "Harenberg et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Harenberg et al\\.",
      "year" : 2011
    }, {
      "title" : "Development of self-microemulsifying drug delivery systems (SMEDDS) for oral bioavailability enhancement of simvastatin in beagle dogs. International journal of pharmaceutics",
      "author" : [ "B.K. Kang", "J.S. Lee", "S.K. Chon", "S.Y. Jeong", "S.H. Yuk", "G. Khang", "H.B. Lee", "S.H. Cho" ],
      "venue" : null,
      "citeRegEx" : "Kang et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Kang et al\\.",
      "year" : 2004
    }, {
      "title" : "optimization, in vitro and in vivo evaluation",
      "author" : [ "A. Khattab", "L. Hassanin", "N. Zaki" ],
      "venue" : "Journal of Molecular Liquids",
      "citeRegEx" : "Khattab et al\\.,? \\Q2017\\E",
      "shortCiteRegEx" : "Khattab et al\\.",
      "year" : 2017
    }, {
      "title" : "coenzyme Q10: formulation development and bioavailability assessment. International journal of pharmaceutics",
      "author" : [ "S. Kuhle", "P. Massicotte", "A. Chan", "M. Adams", "M. Abdolell", "G. de Veber", "L. Mitchell" ],
      "venue" : null,
      "citeRegEx" : "Kuhle et al\\.,? \\Q2004\\E",
      "shortCiteRegEx" : "Kuhle et al\\.",
      "year" : 2004
    }, {
      "title" : "Microemulsion-based media as novel drug delivery systems. Advanced drug delivery reviews",
      "author" : [ "M.J. Lawrence", "G.D. Rees" ],
      "venue" : "X.-W.,",
      "citeRegEx" : "Lawrence and Rees,? \\Q2012\\E",
      "shortCiteRegEx" : "Lawrence and Rees",
      "year" : 2012
    }, {
      "title" : "In vitro and in vivo evaluation of self-nanoemulsifying drug delivery systems of cilostazol for oral and parenteral administration",
      "author" : [ "D.B. Mahmoud", "M.H. Shukr", "E.R. Bendas" ],
      "venue" : "International journal of pharmaceutics 476,",
      "citeRegEx" : "Mahmoud et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Mahmoud et al\\.",
      "year" : 2014
    }, {
      "title" : "Study of cosurfactant effect on nanoemulsifying area and development of lercanidipine loaded (SNEDDS) self nanoemulsifying drug delivery system",
      "author" : [ "N. Parmar", "N. Singla", "S. Amin", "K. Kohli" ],
      "venue" : "Colloids and surfaces. B,",
      "citeRegEx" : "Parmar et al\\.,? \\Q2011\\E",
      "shortCiteRegEx" : "Parmar et al\\.",
      "year" : 2011
    }, {
      "title" : "Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Advanced drug delivery reviews",
      "author" : [ "C.W. Pouton", "C.J. Porter" ],
      "venue" : "Pediatrics",
      "citeRegEx" : "Pouton and Porter,? \\Q2008\\E",
      "shortCiteRegEx" : "Pouton and Porter",
      "year" : 2008
    }, {
      "title" : "Development and bioavailability assessment of ramipril nanoemulsion formulation",
      "author" : [ "Press", "S. USA. Shafiq", "F. Shakeel", "S. Talegaonkar", "F.J. Ahmad", "R.K. Khar", "M. Ali" ],
      "venue" : "European Journal of Pharmaceutics and Biopharmaceutics",
      "citeRegEx" : "Press et al\\.,? \\Q2007\\E",
      "shortCiteRegEx" : "Press et al\\.",
      "year" : 2007
    }, {
      "title" : "Polymeric solid self-nanoemulsifying drug delivery system of glibenclamide using coffee husk as a low cost biosorbent",
      "author" : [ "F. Shakeel", "N. Haq", "F.K. Alanazi", "I.A. Alsarra" ],
      "venue" : "Powder Technology",
      "citeRegEx" : "Shakeel et al\\.,? \\Q2014\\E",
      "shortCiteRegEx" : "Shakeel et al\\.",
      "year" : 2014
    }, {
      "title" : "The usefulness of sugar surfactants as solubilizing agents in parenteral formulations",
      "author" : [ "E. Söderlind", "M. Wollbratt", "C. von Corswant" ],
      "venue" : "AAPS PharmSciTech 10,",
      "citeRegEx" : "Söderlind et al\\.,? \\Q2003\\E",
      "shortCiteRegEx" : "Söderlind et al\\.",
      "year" : 2003
    }, {
      "title" : "Development of a stability-indicating HPLC method and a dissolution test for rivaroxaban dosage forms",
      "author" : [ "E. Souri", "S. Mottaghi", "M. Zargarpoor", "R. Ahmadkhaniha", "H. Jalalizadeh" ],
      "venue" : "Acta Chromatographica",
      "citeRegEx" : "Souri et al\\.,? \\Q2016\\E",
      "shortCiteRegEx" : "Souri et al\\.",
      "year" : 2016
    }, {
      "title" : "Formulation development and optimization of a novel Cremophore EL-based nanoemulsion using ultrasound cavitation",
      "author" : [ "S.Y. Tang", "S. Manickam", "T.K. Wei", "B. Nashiru" ],
      "venue" : "Ultrasonics sonochemistry",
      "citeRegEx" : "Tang et al\\.,? \\Q2012\\E",
      "shortCiteRegEx" : "Tang et al\\.",
      "year" : 2012
    }, {
      "title" : "Pharmacokinetics, tissue distribution, bioavailability, and excretion of nuciferine, an alkaloid from lotus, in rats by LC/MS/MS. Drug development and industrial pharmacy",
      "author" : [ "F. Wang", "J. Cao", "X. Hou", "Z. Li", "X. Qu" ],
      "venue" : null,
      "citeRegEx" : "Wang et al\\.,? \\Q2018\\E",
      "shortCiteRegEx" : "Wang et al\\.",
      "year" : 2018
    }, {
      "title" : "A critical analysis of platelet counting methods. American journal of clinical pathology",
      "author" : [ "R.K. Wertz", "J.A. Koepke" ],
      "venue" : null,
      "citeRegEx" : "Wertz and Koepke,? \\Q1977\\E",
      "shortCiteRegEx" : "Wertz and Koepke",
      "year" : 1977
    } ],
    "referenceMentions" : [ {
      "referenceID" : 8,
      "context" : "Recently, venous thromboembolism (VTE) has been progressively regarded as a severe clinical problem in the paediatric population since it is associated with significant morbidity and mortality in patients, particularly children with serious underlying conditions as cancer and multiple risk factors that were significantly reported in hospitalized children (Kuhle et al., 2004; Raffini et al., 2009).",
      "startOffset" : 357,
      "endOffset" : 399
    }, {
      "referenceID" : 3,
      "context" : "After the oral administration of RIVA, the peak plasma concentration is achieved within 2 to 4 h (Cuker et al., 2014).",
      "startOffset" : 97,
      "endOffset" : 117
    }, {
      "referenceID" : 0,
      "context" : "00 mL/ min flow rate; the detection was done at 249 nm (Abdallah et al., 2015).",
      "startOffset" : 55,
      "endOffset" : 78
    }, {
      "referenceID" : 10,
      "context" : "Then 1 g of each clear mixture was added to a 250 mL of distilled water at 37 oC under gentle stirring of 25 rpm (Mahmoud et al., 2014) where the dispersions were evaluated by visual observation.",
      "startOffset" : 113,
      "endOffset" : 135
    }, {
      "referenceID" : 6,
      "context" : "All mixtures were stored at room temperature for further characterization (Kang et al., 2004).",
      "startOffset" : 74,
      "endOffset" : 93
    }, {
      "referenceID" : 10,
      "context" : "Samples were tested in triplicates (Mahmoud et al., 2014).",
      "startOffset" : 35,
      "endOffset" : 57
    }, {
      "referenceID" : 10,
      "context" : "The efficiency of the self-emulsification process was judged depending on the following grading system (Mahmoud et al., 2014; Shafiq et al., 2007):",
      "startOffset" : 103,
      "endOffset" : 146
    }, {
      "referenceID" : 10,
      "context" : "Percentage transmittance is used as an indicative measure of the optical transparency of the nanoemulsions, therefore the % transmittance of the formed emulsions was assessed at 650 nm by means of UV spectrophotometer (Shimadzu, UV-160, Japan) using distilled water as a blank (Mahmoud et al., 2014).",
      "startOffset" : 277,
      "endOffset" : 299
    }, {
      "referenceID" : 0,
      "context" : "4 was done and samples were evaluated visually for any phase separation or drug precipitation after 50, 100 and 1000 fold dilution with each medium (Abdallah et al., 2015; Mahmoud et al., 2014).",
      "startOffset" : 148,
      "endOffset" : 193
    }, {
      "referenceID" : 10,
      "context" : "4 was done and samples were evaluated visually for any phase separation or drug precipitation after 50, 100 and 1000 fold dilution with each medium (Abdallah et al., 2015; Mahmoud et al., 2014).",
      "startOffset" : 148,
      "endOffset" : 193
    }, {
      "referenceID" : 11,
      "context" : "The polarity of the formed droplet is a very important parameter in evaluating the emulsification efficiency (Parmar et al., 2011).",
      "startOffset" : 109,
      "endOffset" : 130
    }, {
      "referenceID" : 7,
      "context" : "The mean value of three measurements ± SD was recorded (Khattab et al., 2017).",
      "startOffset" : 55,
      "endOffset" : 77
    }, {
      "referenceID" : 0,
      "context" : "The formulated RIVA SNEDDSs were sterilized utilizing autoclaving method at 121 °C and 15 psi for 15 min due to the reported thermal stability of RIVA at high temperatures (Abdallah et al., 2015; Use, 2008).",
      "startOffset" : 172,
      "endOffset" : 206
    }, {
      "referenceID" : 17,
      "context" : "SNEDDSs were evaluated for the microbial growth compared to the control samples (Tang et al., 2012).",
      "startOffset" : 80,
      "endOffset" : 99
    }, {
      "referenceID" : 18,
      "context" : "Blood samples (500 μL) were periodically collected from the retro-orbital venous plexus (Wang et al., 2018) using heparinized needle at 0.",
      "startOffset" : 88,
      "endOffset" : 107
    }, {
      "referenceID" : 5,
      "context" : "Increasing RIVA concentrations dose-dependently inhibit the activity of FXa on the chromogenic peptide and thereby the release of p-NA (Harenberg et al., 2011).",
      "startOffset" : 135,
      "endOffset" : 159
    }, {
      "referenceID" : 19,
      "context" : "Besides, the platelet count was carried out according to the method of Wertz and Koepke (Wertz and Koepke, 1977) using a haemocytometer.",
      "startOffset" : 88,
      "endOffset" : 112
    }, {
      "referenceID" : 11,
      "context" : "Solubility of the investigated drug in each excipient plays a vital role in determining the stability of the designed formulation to avoid any precipitation or phase separation upon experiencing in situ solubilization (Parmar et al., 2011).",
      "startOffset" : 218,
      "endOffset" : 239
    }, {
      "referenceID" : 2,
      "context" : "Subsequently, a lower amount of free energy will be needed to obtain the emulsion which in turn will enhance its thermodynamic stability (Beg et al., 2012).",
      "startOffset" : 137,
      "endOffset" : 155
    }, {
      "referenceID" : 11,
      "context" : "This sedimentation may act as seed crystals that can grow larger by time causing phase separation (Parmar et al., 2011).",
      "startOffset" : 98,
      "endOffset" : 119
    }, {
      "referenceID" : 2,
      "context" : "The increased RIVA % release from the developed SNEDDSs is attributed due to the spontaneous formation of nanoemulsion with reduced globule size that requires low surface free energy at the oil/water interface, which can cause instantaneous solubilization of the drug in dissolution medium (Beg et al., 2012).",
      "startOffset" : 290,
      "endOffset" : 308
    }, {
      "referenceID" : 11,
      "context" : "Moreover, the smaller the globules size of the formed nanoemulsion, the larger the interfacial area that is available for drug dissolution and absorption (Balakumar et al., 2013; Parmar et al., 2011).",
      "startOffset" : 154,
      "endOffset" : 199
    }, {
      "referenceID" : 12,
      "context" : "Since, self-microemulsifying drug delivery systems (SMEDDSs) are the systems that form microemulsions of droplet size ranged from 100 to 250 nm, while SNEDDSs refer to the formulations that form nanoemulsions of droplet size less than 100 nm (Pouton and Porter, 2008).",
      "startOffset" : 242,
      "endOffset" : 267
    }, {
      "referenceID" : 9,
      "context" : "The droplet size decreased as the percentage of the surfactant in the formula increased which may lead to a greater stabilization of the formed droplets (Lawrence and Rees, 2012; Parmar et al., 2011) .",
      "startOffset" : 153,
      "endOffset" : 199
    }, {
      "referenceID" : 11,
      "context" : "The droplet size decreased as the percentage of the surfactant in the formula increased which may lead to a greater stabilization of the formed droplets (Lawrence and Rees, 2012; Parmar et al., 2011) .",
      "startOffset" : 153,
      "endOffset" : 199
    }, {
      "referenceID" : 4,
      "context" : "It was reported that the surfactant can cause the interfacial film to condense and hence to stabilize yielding smaller droplet size, while increasing the amount of the cosurfactant may cause inflation of the film (Fahmy et al., 2015; Hosny and Banjar, 2013).",
      "startOffset" : 213,
      "endOffset" : 257
    }, {
      "referenceID" : 1,
      "context" : "These observations are consistent with earlier reports in literature (Agrawal et al., 2015; Shakeel et al., 2014).",
      "startOffset" : 69,
      "endOffset" : 113
    }, {
      "referenceID" : 14,
      "context" : "These observations are consistent with earlier reports in literature (Agrawal et al., 2015; Shakeel et al., 2014).",
      "startOffset" : 69,
      "endOffset" : 113
    }, {
      "referenceID" : 14,
      "context" : "5) designated uniform droplet size distribution (Balakumar et al., 2013; Shakeel et al., 2014).",
      "startOffset" : 48,
      "endOffset" : 94
    }, {
      "referenceID" : 11,
      "context" : "In relatively small particle size molecules, dispersions confer a high zeta potential that allows the particles to resist aggregation due to the repulsion of the similarly charged particles (Parmar et al., 2011).",
      "startOffset" : 190,
      "endOffset" : 211
    }, {
      "referenceID" : 11,
      "context" : "The higher zeta potential value of F17 than F16 can be explained by the smaller droplet size of the former as in the relatively small droplet size molecules, dispersions confer a high zeta potential that imparts the particles the ability to resist aggregation as a result of the repulsion forces between the similarly charged particles (Parmar et al., 2011).",
      "startOffset" : 336,
      "endOffset" : 357
    }, {
      "referenceID" : 15,
      "context" : "The pH values of both formulations complied with the requirements for the parenteral application as it was reported that a pH limit of 2 to 12 is acceptable for intravenous and intramuscular applications (Söderlind et al., 2003).",
      "startOffset" : 204,
      "endOffset" : 228
    } ],
    "year" : 2019,
    "abstractText" : "The increasing incidence of venous thromboembolism in paediatric population has stimulated the development of liquid anticoagulant formulations. Thus our goal is to formulate a liquid formulation of poorly-water soluble anticoagulant, Rivaroxaban, for paediatric use and to assess the possibility of its intravenous administration in emergencies. Self-nanoemulsifying drug delivery systems (SNEDDS) were developed and characterized. SNEDDS constituents were estimated from the saturated solubility study followed by plotting the corresponding ternary phase diagrams to determine the best self-emulsified systems. Thermodynamic stability, emulsification, dispersibility, robustness to dilution tests, in vitro dissolution, particle size and zeta potential were executed to optimize the formulations. The optimized formulation, that composed of Capryol 90: Tween 20: PEG 300 (5:45:50), increased rivaroxaban solubility (285.7 fold than water), it formed nanoemulsion with a particle size of 16.15 nm, PDI of 0.25 and zeta potential of -21.8. It released 100.83±2.78% of rivaroxaban after 5 minutes. SNEDDS was robust to dilution with oral and parenteral fluids and showed safety to human RBCs. SNEDDS showed enhanced bioavailability after oral and intravenous administration than the oral drug suspension (by 1.25 and 1.26 fold, respectively). Moreover, it exhibited enhanced anticoagulant efficacy in the prevention and treatment of carrageenan-induced thrombosis rat model.",
    "creator" : null
  }
}